Newsbenzinga
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…